- Q3 2026 net loss doubled year-over-year to $183.2M ($1.55 per share) vs. $90.8M ($0.81 per share) in Q3 2025.
- Total cash, cash equivalents and short-term investments stood at $960M as of September 30, 2026.
- Pipeline updates include ongoing VANQUISH Phase 3 and initiated SUNRISE oral Phase 3 trials for VK2735.
?? Negative AI Sentiment (-1.5 / 10)